C

CSL

Develops and delivers biotherapies and vaccines

Associate Director - Global Knowledge Management

Full-Time
No salary listed
Expert
Master's, PhD
King of Prussia, PA, USA+1 moreMore locations: Waltham, MA, USA
Remote
Data & AnalyticsData Management

About the job

Requirements
  • A Master of Science, Master of Library and Information Science/Library Science, or Ph.D. in a science-related field such as Biochemistry or Chemistry, or equivalent education and experience in a knowledge management environment.
  • A minimum of eight years of experience in the pharmaceutical industry.
  • A minimum of eight years of experience in knowledge management, research and development, or medical affairs.
  • Proven leadership skills and experience in the biopharmaceutical industry.
  • Experience with data standards and governance within life science.
  • Extensive understanding of copyright regulations, artificial intelligence, and application programming interface usage.
  • Vendor management and contract negotiation skills, with a focus on research databases and their integration.
  • International experience and fluency in English for professional, scientific, and technical communication.
  • Ability to understand customer needs and deliver solutions that create value and satisfaction.
  • Accountability for achieving goals and delivering high-quality outcomes.
  • Ability to collaborate effectively and influence stakeholders at all organizational levels.
  • Strategic mindset to align decisions and actions with broader organizational goals and market dynamics.
  • Ability to navigate complex dynamics and foster collaboration through clear, respectful communication.
  • Ability to identify and develop key metrics to drive business decisions.
Responsibilities
  • Lead the strategic operations of a sustainable information management, knowledge management, and insight advisory service across the CSL Group.
  • Contribute to CSL data standards and governance programs through project participation, functional leadership, and information management consultation.
  • Manage internal and external resources supporting operations and projects related to the digital information and knowledge management strategy, with a focus on artificial intelligence.
  • Administer, organize, strategically plan, formulate policies for, and manage personnel within the Global Knowledge Management team.
  • Manage the cost center for resources, consulting, and data collection subscriptions, including contract development and negotiations for assets within the role’s scope.
  • Partner with Global Sourcing as required by CSL policy.
  • Ensure CSL has access to information and research needed by the business and maximize the value and use of data collection.
  • Build and maintain professional relationships with internal and external knowledge services, pharmaceutical library resources, industry consortiums, and peer networks.
  • Access, share, and apply relevant scientific, regulatory, and industry information to support organizational goals.
  • Lead, develop, and implement innovative information technologies, systems, and workflows to optimize specialized information delivery models and services.
  • Manage vendor relationships and procurement decisions for knowledge resources, databases, and application programming interfaces.
  • Promote digital innovation, value creation, and a data ownership mindset.
  • Lead global knowledge team members and empower staff through consultative and transformational leadership, development, coaching, and mentoring.
  • Oversee the operations and performance of global systems and platforms, including internal and external information sources.
  • Manage CSL’s Copyright Agency Limited license.
  • Implement business improvement processes through technology integration, continuous improvement, usage metrics, and quality management principles.
  • Develop performance metrics and programs to monitor and improve services and resource utilization.
  • Negotiate, influence, collaborate, and foster high-level stakeholder relationships in a cross-matrix environment to align and integrate strategies, enhance performance, and increase operational efficiencies.
Desired Qualifications
  • Five years of experience in people leadership roles in global organizations.
  • Five years of experience in global library services or a comparable information management responsibility.

About the company

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CSL reported US$176 million FY26 cost savings, ahead of its transformation target.
  • US military flu-vaccine exceptions restored some demand after April 2026 mandate cuts.
  • VarmX’s 2029 coagulation program gives CSL a new high-value pipeline beyond plasma.

What critics are saying

  • FY26 statutory loss hit US$2.6 billion after US$7.1 billion impairments and restructuring.
  • CSL plans US$400 million FY27 savings, implying more closures, layoffs, and execution friction.
  • The U.S. plasma turnaround depends on Horizon 2; failure risks long-term margin collapse.

What makes CSL unique

  • CSL’s FY26 revenue reached US$15.8 billion across plasma, vaccines, and Vifor.
  • Seqirus’ AUJEMFLU won UK and European approvals, backed by Lancet Phase 3 data.
  • HEMGENIX remains Europe’s first approved hemophilia B gene therapy, strengthening CSL Behring.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Yahoo Finance
Oct 8th, 2026
CSL to roll out Haemonetics' NexSys devices across all US plasma centres by end of 2027

Haemonetics shares jumped 12% after the company announced CSL now expects to move all of its current US plasma collection centres to Haemonetics' NexSys devices by the end of 2027. The deal, first disclosed in August, was initially limited to only a portion of CSL's US centres with no timeline. The expanded agreement is significant because losing CSL previously flattened Haemonetics' growth. In fiscal 2026, the company's organic revenue growth was just 1.1%, compared to 9.5% excluding lost CSL sales. Following the surge, Haemonetics trades at approximately 21 times forward earnings, above its five-year average of 19.1 times. The deal is non-exclusive with no minimum purchase requirements, meaning CSL can still modify scope and timing. Management plans to provide further details during its November earnings call.

Pharma Dispatch
Oct 6th, 2026
CSL raises $1.5B from US bond investors to refinance debt

CSL has raised US$1.5 billion through corporate bonds issued in the United States to refinance existing debt. The Australian biotechnology company turned to offshore debt markets for the transaction. The bond issuance allows CSL to manage its capital structure by replacing current borrowings with new financing secured from US investors.

CSL
Sep 21st, 2026
CSL partners with VarmX in a strategic collaboration and option agreement to develop first-in-class investigational coagulation treatment

Melbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s...

PR Newswire
Sep 10th, 2026
CSL Seqirus' triple-enhanced flu vaccine shows superior protection for older adults in Lancet study

CSL Seqirus has published Phase 3 study results in The Lancet Infectious Diseases for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine for older adults. The vaccine, marketed as AUJEMFLU, combines three proven approaches: MF59 adjuvant, cell-based manufacturing, and higher-dose formulation. The randomised study enrolled 7,699 adults aged 50 and older across eight countries. Results demonstrated superiority versus an adjuvanted egg-based comparator across all four influenza strains and age groups. The vaccine showed non-inferiority versus a recombinant vaccine for three of four strains in the 50-plus age group and all four strains in those aged 65-plus. The trivalent formulation received approval from the UK's MHRA and the European Commission earlier this year for adults aged 50 and above. Regulatory submissions have been made in multiple markets.

Yahoo Finance
Aug 17th, 2026
CSL reports 2% drop in annual profit to $3.14B on weak plasma sales

Australian biopharmaceutical company CSL reported a 2% decline in annual profit on Tuesday, as its core plasma division experienced falling revenue. The company posted an underlying net profit after tax of $3.14 billion on a constant currency basis for the year ended 30 June, down from $3.22 billion the previous year. CSL is among the world's leading flu vaccine manufacturers. The results reflect challenges in the plasma business, which forms a significant part of the company's operations.